multiple myeloma

systematic review meta-analysis network meta-analysis

Select immune checkpoint inhibitionAll mechanismproteasome inhibitor All type of patientnewly diagnoseduncoded clinical condition ***--- uncoded (null)       carfilzomibPD1 inhibitors carfilzomibnivolumabpembrolizumab      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	death (overall survival) (5)progression or death (progression free survival PFS) (2) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	death (overall survival)	progression or death (progression free survival PFS)
All mechanism
not classified
CLARION    NCT	carfilzomib					-
NCT01863550    NCT	carfilzomib					-
ELOQUENT - 1    NCT	Elotuzumab Lenalidomide Dexamethasone	Lenalidomide + Dexamethasone			Risk of bias	-
ELOQUENT - 2    NCT	Elotuzumab Lenalidomide Dexamethasone	Lenalidomide + Dexamethasone				-
MRC Myeloma IX	CTDa	MP				-
MM-015      NCT	MPR+R	MP				-
IFM 01/01	MPT	MP				-
IFM 99/06      NCT	MPT	MP				-
NCT01274403      NCT	MPT	MP				-
GIMEMA      NCT	MPT+T	MP				-
HOVON 49	MPT+T	MP				-
NMSG	MPT+T	MP				-
TMSG      NCT	MPT+T	MP				-
VISTA      NCT	VMP	MP				-
FIRST      NCT	Rd ou Rd18	MPT				-
EIA06 (NCT00602641)    NCT	MPR+R	MPT+T				-
NR 1997	PCAB+IFN-2a	PCAB				-
ASPIRE, 2015      NCT	carfilzomib	placebo (on top lenalidomide and dexamethasone)			Risk of bias	suggesting
ELOQUENT 2, 2015      NCT	elotuzumab	placebo (on top lenalidomide and dexamethasone)			Risk of bias	negative
NR 2013	MPR + CPR	Rd				-
NCT00911859      NCT	VMP + siltuximab	VMP				-
NR 2010	VMPT+VT	VMP				-
immune checkpoint inhibition
pembrolizumab
KEYNOTE-185, 2018    NCT	pembrolizumab, lenalidomide, dexametahsone	lenalidomide, dexamethasone	not eligible for ASCT		Risk of bias	remark
KEYNOTE-183, 2018    NCT	pembrolizumab + pomadoline + dexamethasone	pomadoline + dexamethasone	rrMM		Risk of bias	negative
proteasome inhibitor
carfilzomib
ENDEAVOR, 2016          NCT	carfilzomib	bortezomib	relapsed MM		Risk of bias	suggesting
ECOG-ACRIN    NCT	carfilzomib	bortezomid				-
CLARION    NCT	carfilzomib	bortezomid				-
ASPIRE, 2014            NCT	carfilzomib lenalidomide dexamethasone	lenalidomide and dexamethasone alone	relapsed MM		Risk of bias	suggesting
FOCUS, 2017        NCT	carfilzomib	low-dose corticosteroids	relapsed and refractory multiple myeloma (RRMM)		Risk of bias	negative